BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21183948)

  • 1. Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus.
    Zhou W; Zhu H; Chen W; Hu X; Pang X; Zhang J; Huang X; Fang B; He C
    Cancer Gene Ther; 2011 May; 18(5):336-45. PubMed ID: 21183948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
    Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
    Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes.
    Lin T; Gu J; Zhang L; Huang X; Stephens LC; Curley SA; Fang B
    Cancer Res; 2002 Jul; 62(13):3620-5. PubMed ID: 12097263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene.
    Cao X; Yang M; Wei RC; Zeng Y; Gu JF; Huang WD; Yang DQ; Li HL; Ding M; Wei N; Zhang KJ; Xu B; Liu XR; Qian QJ; Liu XY
    Gene Ther; 2011 Aug; 18(8):765-77. PubMed ID: 21412282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL.
    Liu X; Cao X; Wei R; Cai Y; Li H; Gui J; Zhong D; Liu XY; Huang K
    Cancer Gene Ther; 2012 Jan; 19(1):49-57. PubMed ID: 21979578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conditionally replicating adenovirus improves gene replication efficiency and anticancer effect of E1-deleted adenovirus carrying TRAIL in head and neck squamous cell carcinoma.
    Shim SH; Lee CT; Hun Hah J; Lee JJ; Park SW; Heo DS; Sung MW
    Cancer Sci; 2010 Feb; 101(2):482-7. PubMed ID: 19922505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.
    Dong F; Wang L; Davis JJ; Hu W; Zhang L; Guo W; Teraishi F; Ji L; Fang B
    Clin Cancer Res; 2006 Sep; 12(17):5224-30. PubMed ID: 16951242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter.
    Jacob D; Davis J; Zhu H; Zhang L; Teraishi F; Wu S; Marini FC; Fang B
    Clin Cancer Res; 2004 May; 10(10):3535-41. PubMed ID: 15161713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
    Wang H; Wei F; Li H; Ji X; Li S; Chen X
    Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma.
    Ye X; Lu Q; Zhao Y; Ren Z; Ren XW; Qiu QH; Tong Y; Liang M; Hu F; Chen HZ
    Int J Mol Med; 2005 Dec; 16(6):1179-84. PubMed ID: 16273304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and canstatin gene suppression therapy on breast tumor xenograft growth in mice.
    Wang WB; Zhou YL; Heng DF; Miao CH; Cao YL
    Breast Cancer Res Treat; 2008 Jul; 110(2):283-95. PubMed ID: 17899369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene.
    Kagawa S; He C; Gu J; Koch P; Rha SJ; Roth JA; Curley SA; Stephens LC; Fang B
    Cancer Res; 2001 Apr; 61(8):3330-8. PubMed ID: 11309289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer.
    Zhao L; Dong A; Gu J; Liu Z; Zhang Y; Zhang W; Wang Y; He L; Qian C; Qian Q; Liu X
    Cancer Gene Ther; 2006 Nov; 13(11):1011-22. PubMed ID: 16799468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation-inducible human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy: a novel treatment for radioresistant uveal melanoma.
    Zhou Y; Song X; Jia R; Wang H; Dai L; Xu X; Gu P; Ge S; Fan X
    Pigment Cell Melanoma Res; 2010 Oct; 23(5):661-74. PubMed ID: 20546535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft.
    Huang X; Lin T; Gu J; Zhang L; Roth JA; Stephens LC; Yu Y; Liu J; Fang B
    Gene Ther; 2002 Oct; 9(20):1379-86. PubMed ID: 12365003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2.
    Schepelmann S; Ogilvie LM; Hedley D; Friedlos F; Martin J; Scanlon I; Chen P; Marais R; Springer CJ
    Cancer Res; 2007 May; 67(10):4949-55. PubMed ID: 17510425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
    Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy.
    Bernt KM; Ni S; Tieu AT; Lieber A
    Cancer Res; 2005 May; 65(10):4343-52. PubMed ID: 15899826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice.
    Pei Z; Chu L; Zou W; Zhang Z; Qiu S; Qi R; Gu J; Qian C; Liu X
    Hepatology; 2004 May; 39(5):1371-81. PubMed ID: 15122766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.